Merck (MRK) Liabilities and Shareholders Equity (2009 - 2026)

Merck (MRK) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $128.7 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $128.7 billion, up 11.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $512.6 billion (up 10.86% YoY), and the FY2025 annual result was $136.9 billion, up 16.87% from the prior year.
• Liabilities and Shareholders Equity eased to $128.7 billion in Q1 2026 per MRK's latest filing, from $136.9 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $136.9 billion in Q4 2025 and troughed at $104.5 billion in Q2 2023.
• A 5-year average of $113.9 billion and a median of $109.2 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity advanced 18.09% in 2022, then retreated 2.45% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $109.2 billion in 2022, then retreated by 2.28% to $106.7 billion in 2023, then gained by 9.78% to $117.1 billion in 2024, then gained by 16.87% to $136.9 billion in 2025, then decreased by 5.98% to $128.7 billion in 2026.
• Business Quant data shows MRK's Liabilities and Shareholders Equity at $128.7 billion in Q1 2026, $136.9 billion in Q4 2025, and $129.5 billion in Q3 2025.